The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
FDA’s requirement for truthful, balanced risk and benefit information applies to drugmakers, leaving a loophole for both ...
Once again, Dupixent finished in second place with an impressions SOV ... For the pharma industry, the MLB playoffs delivered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback